This wide-ranging presentation introduces advocates to cabotegravir injectable PrEP. The slides provide a background on clinical research, what users think, regulatory status and prepares advocates for implementation.
CAB for PrEP for Advocates
Basics of Injectable Cabotegravir for HIV Prevention
Celebrating the Role of Communities: A focus on choice in HIV prevention
Presentation given by Rosemary Mburu, Executive Director of WACI Health, on World AIDS Day 2022 describing her organization and providing a short overview of the field.
HIV Testing for Advocates
Basics of HIV Testing and Implications for HIV Prevention
This slide deck provides and overview of HIV testing—types of test, WHO guidelines, current issues in testing, looking ahead, resources and more.
Product Introduction for Advocates
Basic Elements of Product Introduction for HIV Prevention
This slide deck provides an overview of product introduction, the process of moving products to the “real world”— an interrelated set of actions needed for global and national health systems to incorporate and deliver new, improved or underused technologies.
What’s New & Next in HIV Prevention
A quick but comprehensive slideshow review by AVAC Executive Director Mitchell Warren reviewing the state of HIV prevention, forthcoming products, and what needs to come next. Much accomplished; much to do.
Download the original PPT.
HIV Vaccines: The basics
This introductory PowerPoint slide set reviews basic concepts, and provides an overview of research status and recent developments.
The Evolution of Oral PrEP Access
A presentation on global trends in PrEP uptake since 2016, prepared for R4P. See breakdowns by country and analysis of lessons learned and continued use.
The Next-Generation of Biomedical Prevention: Now What
Slides presented by AVAC Executive Director Mitchell Warren at the PEPFAR Scientific Advisory Board meeting taking place over October 7-8, 2020.
A Roadmap for Results: Understanding the ECHO Study Results
On June 13, FP2020 and AVAC held a webinar, A Roadmap for Results: Understanding the ECHO Study Results, with the ECHO team following the results announcement. The webinar explained the trial, provided topline results, outlined next steps, and offered key advocacy messages to help all stakeholders understand the findings.
Watch here.
Hormonal Contraception and HIV Risk: Understanding the ECHO trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.
Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.
The webinar featured:
Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020
You may view the webinar here.